{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:58:24Z","timestamp":1781143104529,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109444","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:12:09Z","timestamp":1778339529000},"page":"109444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Upfront management of brain metastases in oncogene\u2011addicted NSCLC \u2013 An EORTC survey"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2865-1855","authenticated-orcid":false,"given":"Ana","family":"Ortega-Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-5268","authenticated-orcid":false,"given":"Ilias","family":"Houda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-7413","authenticated-orcid":false,"given":"Thomas","family":"Pierret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-5249","authenticated-orcid":false,"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-0319","authenticated-orcid":false,"given":"Niccolo","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-2519","authenticated-orcid":false,"given":"Thierry","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-9781","authenticated-orcid":false,"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109444_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102807","article-title":"Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape","volume":"130","author":"Weller","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109444_b0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: a Systematic Review and Meta-Analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0020","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.2015.60.9503","article-title":"Treatment of Brain Metastases","volume":"33","author":"Lin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109444_b0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"J\u00e4nne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109444_b0035","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109444_b0040","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib Versus Crizotinib in patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes from the phase III CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib Versus Crizotinib in ALK Inhibitor\u2013Naive Advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L Trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annonc.2025.09.018","article-title":"Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study\u2606","volume":"37","author":"Peters","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0055","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion\u2013Positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109444_b0060","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in locally Advanced or Metastatic ROS1 Fusion-positive Non-Small-Cell Lung Cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0065","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Rhun","year":"2021","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.lungcan.2026.109444_b0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0075","article-title":"Emerging Systemic Treatment Perspectives on Brain Metastases: moving Toward a Better Outlook for patients","volume":"147\u2013165","author":"Alvarez-Breckenridge","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2026.109444_b0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0085","article-title":"Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: the STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials","volume":"103549","author":"Lee","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0090","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1200\/JCO.23.02668","article-title":"Tyrosine Kinase Inhibitors with and without Up-Front Stereotactic Radiosurgery for Brain Metastases from EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC)","volume":"42","author":"Pike","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0095","article-title":"ESMO\u2013ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors","author":"van Aken","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0100","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer with CNS failure to prior EGFR Tyrosine Kinase Inhibitors: a Nonrandomized Controlled Trial","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109444_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non\u2013Small Cell Lung Cancer with or without Brain Metastases: a Secondary Analysis of Randomized Clinical Trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2026.109444_b0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109444_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100819","article-title":"Globalization of precision medicine programs in lung cancer: a health system challenge","volume":"36","author":"Rolfo","year":"2024","journal-title":"The Lancet Regional Health \u2013 Europe"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:13:55Z","timestamp":1781140435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S0169500226005052"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109444","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront management of brain metastases in oncogene\u2011addicted NSCLC \u2013 An EORTC survey","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109444"}}